Precipio's BCR::ABL1 Assay Presentation at ASH Meeting
NEW HAVEN, Conn. — Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is preparing to showcase its BCR::ABL1 panel at an upcoming prominent medical conference. The presentation will highlight significant findings from a collaborative study conducted alongside researchers from notable institutions.
Study Overview
The comprehensive study involved a substantial cohort of 895 patient samples, demonstrating the superior performance of Precipio's BCR::ABL1 assay. The results illustrate how this innovative assay exhibits high concordance with prevailing testing platforms, thus affirming its reliability in clinical applications.
Impact on Patient Care
The implications of this research are vast, showing clear, positive influences on patient care. Better diagnostic accuracy not only leads to improved patient outcomes but also enhances laboratory workflows, paving the way for a more efficient healthcare process.
ASH Meeting Details
Scheduled for Monday, December 8th, the poster session will take place from 6:00 PM to 8:00 PM at the OCCC room in West Halls B3-B4 at the ASH Meeting in Orlando, Florida. Attendees will be able to engage with data presentations and discussions concerning these vital findings.
About Precipio
As a leading healthcare biotechnology company, Precipio is dedicated to revolutionizing cancer diagnostics. The company’s mission centers around reducing instances of cancer misdiagnosis through the development of cutting-edge diagnostic products and services. By improving accuracy and laboratory efficiency, Precipio aims to enhance patient outcomes while simultaneously reducing healthcare costs. The company focuses on creating innovative diagnostic technologies that are clinically validated, ultimately serving the global laboratory community and addressing the critical issue of misdiagnosis.
Connect With Precipio
For more information about Precipio and its advancements in cancer diagnostics, visit their website at https://www.precipiodx.com or follow them on various social media platforms including X (formerly Twitter) and LinkedIn where they regularly post updates about their projects and initiatives.
Frequently Asked Questions
What is the significance of the BCR::ABL1 assay?
The BCR::ABL1 assay is crucial for accurately diagnosing and monitoring certain types of leukemia, helping improve patient treatment plans.
When will the findings be presented?
The findings will be presented on December 8th from 6:00 PM to 8:00 PM at the ASH Meeting in Orlando.
How many patient samples were involved in the study?
The study included 895 patient samples, providing a robust dataset to validate the new assay.
What are the key benefits of this assay?
Benefits include enhanced diagnostic accuracy, improved laboratory efficiency, and better overall patient outcomes.
How can I stay updated on Precipio’s developments?
You can follow updates on their official website and social media channels, where they share news and information regularly.
